Kerry Holford
Stock Analyst at Berenberg Bank
(3.85)
# 1,981
Out of 4,659 analysts
243
Total ratings
56.6%
Success rate
8.5%
Average return
Main Sectors:
Stocks Rated by Kerry Holford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Hold | 2,000p | 1,888p | +5.93% | 50 | Aug 17, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Downgraded: Hold | kr 325.00 → kr 305.00 | kr 292.26 | +4.36% | 42 | Aug 12, 2026 | |
| NVO Novo Nordisk | Downgraded: Hold | $47 | $45.71 | +2.82% | 8 | Aug 11, 2026 | |
| PFE Pfizer | Maintained: Hold | $25 | $27.25 | -8.26% | 31 | Aug 5, 2026 | |
| NVS Novartis AG | Maintained: Hold | $141 → $147 | $154.55 | -4.89% | 9 | Jul 27, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 92.00 → CHF 120.00 | CHF 125.56 | -4.43% | 41 | Jul 27, 2026 | |
| LLY Eli Lilly and Company | Maintained: Hold | $1,135 | $1,225.73 | -7.40% | 31 | Jul 16, 2026 | |
| LON: 0NZT UCB SA | Maintained: Buy | €130.00 → €305.00 | €217.30 | +40.36% | 3 | Jul 2, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | $128 → $46 | $49.07 | -5.31% | 4 | Jun 16, 2026 | |
| GSK GSK plc | Maintained: Hold | $41 → $43 | $51.15 | -15.93% | 14 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €105.00 → €120.00 | €77.67 | n/a | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €1.60 | €1.83 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $60 | $84.27 | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 100p | 44p | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €150.00 | €136.75 | n/a | 1 | Apr 16, 2021 |
GSK plc
Aug 17, 2026
Maintained: Hold
Price Target: 2,000p
Current: 1,888p
Upside: +5.93%
Novo Nordisk A/S
Aug 12, 2026
Downgraded: Hold
Price Target: kr 325.00 → kr 305.00
Current: kr 292.26
Upside: +4.36%
Novo Nordisk
Aug 11, 2026
Downgraded: Hold
Price Target: $47
Current: $45.71
Upside: +2.82%
Pfizer
Aug 5, 2026
Maintained: Hold
Price Target: $25
Current: $27.25
Upside: -8.26%
Novartis AG
Jul 27, 2026
Maintained: Hold
Price Target: $141 → $147
Current: $154.55
Upside: -4.89%
Novartis AG
Jul 27, 2026
Maintained: Hold
Price Target: CHF 92.00 → CHF 120.00
Current: CHF 125.56
Upside: -4.43%
Eli Lilly and Company
Jul 16, 2026
Maintained: Hold
Price Target: $1,135
Current: $1,225.73
Upside: -7.40%
UCB SA
Jul 2, 2026
Maintained: Buy
Price Target: €130.00 → €305.00
Current: €217.30
Upside: +40.36%
Zealand Pharma A/S
Jun 16, 2026
Downgraded: Hold
Price Target: $128 → $46
Current: $49.07
Upside: -5.31%
GSK plc
Nov 25, 2025
Maintained: Hold
Price Target: $41 → $43
Current: $51.15
Upside: -15.93%
May 16, 2025
Maintained: Buy
Price Target: €105.00 → €120.00
Current: €77.67
Upside: n/a
Apr 1, 2025
Maintained: Hold
Price Target: €1.60
Current: €1.83
Upside: n/a
Mar 24, 2025
Maintained: Hold
Price Target: $65 → $60
Current: $84.27
Upside: n/a
Mar 24, 2025
Maintained: Buy
Price Target: 100p
Current: 44p
Upside: n/a
Apr 16, 2021
Maintained: Hold
Price Target: €150.00
Current: €136.75
Upside: n/a